Ocrelizumab: Additional Phase II data

Additional data from an ongoing, 96-week, dose-finding Phase II trial in 220 patients with RRMS showed that 600 and 2,000 mg ocrelizumab significantly reduced the number of

Read the full 272 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE